These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9138059)

  • 1. A dose-response study of alprostadil sterile powder (S.Po.) (Caverject) for the treatment of erectile dysfunction in Korean and Indonesian men.
    Choi HK; Adimoelja A; Kim SC; Soebadi DM; Seong DH; Garceau RJ
    Int J Impot Res; 1997 Mar; 9(1):47-51. PubMed ID: 9138059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction.
    Colli E; Calabrò A; Gentile V; Mirone V; Soli M
    Eur Urol; 1996; 29(1):59-62. PubMed ID: 8821692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of alprostadil sterile powder in a home self-injection study of Asian men with erectile dysfunction.
    Wu CC; Xue ZY; Apichat K; Huang ST; He Z; Garceau RJ
    Clin Ther; 1996; 18(2):256-64. PubMed ID: 8733986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
    Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction.
    Tsai YS; Lin JS; Lin YM
    Eur Urol; 2000 Aug; 38(2):177-83. PubMed ID: 10895010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
    Tang SF; Chu NK; Wong MK
    Paraplegia; 1995 Dec; 33(12):731-3. PubMed ID: 8927414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea.
    Kim SC; Ahn TY; Choi HK; Choi NG; Chung TG; Chung WS; Hwang TK; Hyun JS; Jung GW; Kim CI; Kim JJ; Kim SW; Lee CH; Lee KS; Lee WH; Min KS; Moon KH; Paic JS; Park KS; Park NC; Park YK; Seo JK; Seo KK; Shin JS; Yoon YR; Lee WC
    Int J Impot Res; 2000 Apr; 12(2):97-101. PubMed ID: 11052635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Alprostadil Study Group.
    Vanderschueren D; Heyrman RM; Keogh EJ; Casey RW; Weiske WH; Ogrinc FG; de Koning Gans HJ
    J Urol; 1995 Nov; 154(5):1744-7. PubMed ID: 7563337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Intracavernosal Injection of Prostaglandin E1 on Duration and Rigidity of Erection in Patients With Vasculogenic Erectile Dysfunction: Is It Dose Dependent?
    Bassiem MA; Ismail IY; Salem TA; El-Sakka AI
    Urology; 2021 Feb; 148():173-178. PubMed ID: 33017615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
    Linet OI; Ogrinc FG
    N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.
    Bratus D; Hlebic G; Hajdinjak T
    Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic.
    Armstrong DK; Convery A; Dinsmore WW
    Ulster Med J; 1994 Apr; 63(1):18-22. PubMed ID: 8658990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with intracavernous PGE-1 in the treatment of erectile dysfunction: dose considerations and efficacy.
    Ismail M; Abbott L; Hirsch IH
    Int J Impot Res; 1997 Mar; 9(1):39-42. PubMed ID: 9138057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Alprostadil (Caverject) and a combination of vasoactive drugs as local injections for the treatment of erectile dysfunction.
    Abdallah HM
    Int Urol Nephrol; 1998; 30(5):617-20. PubMed ID: 9934808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
    Kunelius P; Lukkarinen O
    Int J Impot Res; 1999 Feb; 11(1):21-4. PubMed ID: 10098949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The intracavernous injection of Edex (prostaglandin E1) in the treatment of erectile impotence in persons in older age groups].
    Gorilovskiĭ LM
    Urol Nefrol (Mosk); 1996; (6):31-3. PubMed ID: 9036606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction.
    Chen J; Godschalk M; Katz PG; Mulligan T
    J Urol; 1995 Jan; 153(1):80-1. PubMed ID: 7966797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men.
    Heaton JP; Lording D; Liu SN; Litonjua AD; Guangwei L; Kim SC; Kim JJ; Zhi-Zhou S; Israr D; Niazi D; Rajatanavin R; Suyono S; Benard F; Casey R; Brock G; Belanger A
    Int J Impot Res; 2001 Dec; 13(6):317-21. PubMed ID: 11918246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
    Engel JD; McVary KT
    Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil.
    Hellstrom WJ; Bennett AH; Gesundheit N; Kaiser FE; Lue TF; Padma-Nathan H; Peterson CA; Tam PY; Todd LK; Varady JC; Place VA
    Urology; 1996 Dec; 48(6):851-6. PubMed ID: 8973666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.